More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
The findings contradict prior research that utilized the same software, experts involved in the research noted. This could be due to out-of-distribution data for the DL software, which could impair its performance.
Recent evidence confirms that interventional radiology produces solid clinical outcomes while beating surgery on the cost-effectiveness of numerous procedures.
Atul Verma, MD, director of cardiology at McGill University Health Centre in Montreal, explained why the late-breaking PULSED-AF trial data on Medtronic’s pulsed-field ablation technology is so important for cardiologists.
In comparison to a cohort of individuals who were unaffected by either condition, the differences in brain stem volume were found to be significant, according to a paper published recently in Frontiers in Neuroscience.
